Fig. 1.

Eight defined sites of radiographic involvement of LC-LM. (A) Cerebrum. (B) Ventricle. (C) Brainstem (pons and medulla included in this category). (D) Cerebellum. (E) Cranial nerves. (F) Cervical spinal cord. (G) Thoracic spinal cord. (H) Lumbosacral spinal cord. (I) Among the 76 patients with complete staging of LC-LM who did not receive bevacizumab within 30 days prior to MRI, there was a significantly increased risk of death with 3+ radiographic sites of disease versus 0–2 sites of disease (HR for 3+ sites of disease: 1.95; 95% CI: 1.16–3.30; P = 0.01).